NMP and NEP

These substances were identified for action under the Chemicals Management Plan (CMP).

• Summary of publications
• Timelines
• Background

Summary of publications

CAS RN	Common name (abbreviation)	DSL name	Public comments on the first draft screening assessment	Updated draft assessment	Risk management scope	Proposed conclusion on section 64 criteria	Follow-up activities
872-50-4	N-Methylpyrrolidone (NMP)	2-Pyrrolidinone, 1-methyl	HTML	HTML	HTML	Meets one or more of the criteria	Refer to risk management scope
2687-91-4	N-Ethylpyrrolidone (NEP)	2-Pyrrolidinone, 1-ethyl			None	Does not meet	Under consideration

Timelines

Date	Activity
January 2025	Anticipated publication of the final assessment and proposed risk management approach.
January 27, 2024	Publication and start of a 60-day public comment period on the Updated Draft Screening Assessment for NMP and NEP (including follow-up activities for NEP) and the Risk Management Scope for 2-pyrrolidinone, 1-methyl- (NMP). The related notice was published in the Canada Gazette, Part I: Vol. 158, No. 4.
February 4, 2017	Publication and start of 60-day public comment period on the first draft screening assessment (including follow-up activities). The related notice was published in the Canada Gazette, Part I: Vol. 151, No. 5.

Background

A draft screening assessment for NMP and NEP was published in February 2017. Since then, new information became available regarding exposure to products available to consumers containing NMP and NEP that had the potential to alter assessment conclusions. As a result, the draft screening assessment was updated.